All In Biotech

NDA 020031 · Apotex

Paxil

Paroxetine Hydrochloride · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Dec 29, 1992

Approved uses

7

Original approval plus efficacy supplements

Registered trials

275

60 Phase 3, 11 recruiting

FAERS reports

54,135

33,774 serious, 3,560 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . PAXIL is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning . Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) PAXIL is not approved for use in pediatric patients ( 5.1 , 8.4 )

What it is approved for

From the label in effect Sep 29, 2026.

PAXIL is indicated in adults for the treatment of: Major depressive disorder (MDD) in adults Obsessive compulsive disorder (OCD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Generalized anxiety disorder (GAD) in adults Posttraumatic stress disorder (PTSD) in adults PAXIL is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): Major depressive disorder (MDD) in adults Obsessive compulsive disorder (OCD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Generalized anxiety disorder (GAD) in adults Posttraumatic stress disorder (PTSD) in adults

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • PAXIL · PAROXETINE HYDROCHLORIDE EQ 50MG BASE · TABLET, ORAL · Discontinued
  • PAXIL · PAROXETINE HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • PAXIL · PAROXETINE HYDROCHLORIDE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • PAXIL · PAROXETINE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription · TE AB
  • PAXIL · PAROXETINE HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Paroxetine" as an intervention, any sponsor and status, largest first.

All 275 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug withdrawal syndrome5,459
  • nausea4,157
  • drug ineffective3,844
  • dizziness3,820
  • anxiety3,794
  • fatigue3,606
  • headache3,242
  • depression3,143
  • drug exposure during pregnancy2,902
  • insomnia2,645
  • diarrhoea2,401
  • weight increased2,350

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,814
20055,231
20064,161
20072,391
20082,508
20092,432
20102,821
20112,916
20122,742
20131,639
20141,702
20153,347
20163,009
20171,872
20181,636
20191,678
20201,452
20211,317
20221,262
20231,151
20241,179
20251,076
2026793

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Paxil (Paroxetine HCl)

2024 spending

$1.7M

Beneficiaries

624

2,944 claims

Per beneficiary

$2,674

$9.40 per unit

View as table
YearSpending
2020$3,869,382
2021$3,876,607
2022$2,752,938
2023$1,903,999
2024$1,668,362

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,399 on PubMed

Sponsor: Apotex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.